# Jonathan Matlock

> Jonathan Matlock is a seed investor at Empirical Ventures backing Medical and Biotechnology. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures)
- Location: Bedford, United Kingdom
- Total investments: 12
- Last investment: Jul 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/johnathanmatlock

Jonathan Matlock is a seed investor at Empirical Ventures in Bedford focused on Medical and Biotechnology. Co-Founder @ Empirical Ventures | Scientist | Entrepreneur | Investor | PhD Chemistry

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 6 | 50% |
| Biotechnology | 4 | 33% |
| Health Care | 3 | 25% |
| Medical Device | 3 | 25% |
| Life Science | 2 | 17% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 83% |
| Funding Round | 2 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Healome Therapeutics | Healome Therapeutics | $2.7M | Seed | Jul 07, 2026 |  |
| Neuronostics | Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP. | $4M | Seed | Jun 30, 2026 |  |
| Caudal Energy | Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics. | $5.8M | Seed | May 27, 2026 |  |
| QV Bioelectronics | Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $6M |  | Jan 21, 2026 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M | Seed | Aug 28, 2025 |  |
| OutSee | OutSee creates cutting-edge computational methods for genomics for the development of therapeutic targets and precision medicine. | $3.4M | Seed | Jun 24, 2025 |  |
| OSSTEC | OSSTEC is bringing advanced technology to the operating room with metal 3D printed bone healing implants. The orthopaedic implants emulate natural bone structure and address high failure rates of existing implants, keeping patients who suffer with osteoarthritis healthy, active and enjoying life. | $3.2M | Seed | Mar 30, 2025 |  |
| MintNeuro | MintNeuro is pioneering the use of semiconductor technology in next-generation neural implants. | $1.3M | Seed | Nov 12, 2024 |  |
| Argonaute RNA | Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. They show how their proprietary modification of smallinterfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. | $2.3M |  | Jul 17, 2024 |  |
| Halo Therapeutics | Halo Therapeutics develops antivirals to prevent users from sickness. It researches on virus shapes and creates fatty acids into medicine to lock them. Halo Therapeutics was founded in 2020 and is based in Bristol, England. | $1.9M | Seed | May 17, 2023 |  |

10 of 12 investments shown.

## Co-investors
- [The Fink Family Office](https://shizune.co/investors/profile/the-fink-family-office) — VC Fund, 3 deals together
- [Angel Investors Bristol](https://shizune.co/investors/profile/angel-investors-bristol) — VC Fund, 2 deals together
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund, 2 deals together
- [Hermesa](https://shizune.co/investors/profile/hermesa) — VC Fund, 2 deals together
- [Kadmos Capital](https://shizune.co/investors/profile/kadmos-capital-43dd) — VC Fund, 2 deals together
- [Panacea Innovation](https://shizune.co/investors/profile/panacea-innovation) — VC Fund, 2 deals together

## About Empirical Ventures

VC Fund · Bristol, United Kingdom

Empirical Ventures supports innovative approaches to critical problems in the fields of biotechnology and life sciences.

2 contacts available at Empirical Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Jonathan Matlock | Co-Founder | https://shizune.co/investors/profile/dr-jonathan-matlock |
| Johnathan Matlock | Co-Founder | https://shizune.co/investors/profile/johnathan-matlock |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Jonathan Matlock invest in?

Jonathan Matlock invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jonathan Matlock last invest?

The most recent investment recorded for Jonathan Matlock closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co